Becton, Dickinson and Company
Thesis
Becton Dickinson is a medical device company trading at around 12.5 times next-twelve months earnings, which is cheap for a quality compounder. The company is poised for earnings growth due to an operational efficiency program and the sale of its biosciences business, which will enhance margins and allow for stock buybacks. The medical device industry is currently undervalued compared to the broader market, making it a rich hunting ground for investments.
Did it work?
No price performance data and no elapsed-time information are provided, so the core claim — that the cheap valuation would re-rate as earnings grew — cannot be tested. Some thesis elements have public corroboration (BD announced plans to separate/sell its biosciences business and has run cost-efficiency programs), but with an unknown pitch date it is impossible to confirm these occurred after the pitch or to measure any resulting return. Without either a measurable return or a clearly dated catalyst confirmation, the thesis can be judged neither worked nor failed.